Current investigations into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are demonstrating promising effects in managing obesity and diabetes second-type diabetes. Preclinical evidence suggest a novel https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/